Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 11/20 | 0.97 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.70 |
| ▸ | HRH1 | P35367 | 2/20 | 0.70 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.70 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.70 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.70 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.70 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.70 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.70 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.70 |
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.70 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.68 |
| ▸ | HTR2C | P28335 | 1/20 | 0.68 |
| ▸ | HTR7 | P34969 | 1/20 | 0.68 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.68 |
| ▸ | LTA4H | P09960 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL491655 | 0.98 | HRH3 (1.00) | HRH3SLC6A2HRH1SLC6A3CHRM2 | |
| SCHEMBL6570265 | 0.90 | HRH3 (0.84) | HRH3SLC6A2HRH1SLC6A3CHRM2 | |
| SCHEMBL6566705 | 0.88 | HRH3 (0.80) | HRH3SLC6A2HRH1SLC6A3CHRM2 | |
| SCHEMBL5302082 | 0.86 | LTA4H (0.86) | HRH3SLC6A3SIGMAR1LTA4H | |
| SCHEMBL22440218 | 0.85 | LTA4H (0.77) | HRH3HRH1SLC6A3SIGMAR1LTA4H | |
| SCHEMBL13962664 | 0.85 | HRH3 (0.77) | HRH3SLC6A2HRH1SLC6A3CHRM2 | |
| SCHEMBL491564 | 0.84 | SIGMAR1 (0.76) | HRH3SIGMAR1 | |
| SCHEMBL8935099 | 0.84 | SIGMAR1 (0.96) | HRH3HRH1SLC6A3SIGMAR1LTA4H | |
| SCHEMBL83687 | 0.84 | SIGMAR1 (0.86) | HRH3SLC6A3SIGMAR1LTA4H | |
| SCHEMBL491979 | 0.84 | HRH3 (0.71) | HRH3SLC6A2HRH1SLC6A3CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1863487-B1 | TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET SOC CIV (FR) | 2013-05-29 | — | — | EP | claimed |
| US-20090318433-A1 | VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE | BIOPROJET (FR) | 2009-12-24 | — | — | US | claimed |
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2009-03-26 | — | — | US | claimed |
| EP-1863487-A2 | TREATMENT OF PARKINSON'S DISEASE, OBSTRUCTIVE SLEEP APNEA, DEMENTIA WITH LEWY BODIES, VASCULAR DEMENTIA WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-12 | — | — | EP | claimed |
| EP-1863486-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2007-12-12 | — | — | EP | claimed |
| US-7169928-B2 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SOCIETE CIVILE BIOPROJECT (FR) | 2007-01-30 | — | — | US | claimed |
| US-7138413-B1 | Administering tertiary amines, e.g., 3,3-Dimethylbutyl 3-piperidinopropyl ether, 3-Phenylpropyl 3-piperidinopropyl ether, or3-(4-Chlorophenyl)propyl 3-piperidinopropyl ether to treat cognitive disorders such as attention, wakefulness and memory disorders | SOCIETE CIVILE BIOPROJET (FR) | 2006-11-21 | — | — | US | claimed |
| WO-2006103546-A2 | TREATMENT OF PARKINSON'S DISEASE, OBSTRUCTIVE SLEEP APNEA, DEMENTIA WITH LEWY BODIES, VASCULAR DEMENTIA WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-10-05 | — | — | WO | claimed |
| WO-2006103537-A2 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | BIOPROJET (FR) | 2006-10-05 | — | — | WO | claimed |
| EP-1707204-A1 | Treatment of epilepsy with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1707203-A1 | Treatment of parkinson's disease obstructive sleep apnea, dementia with lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3- receptor ligands | BIOPROJET (FR) | 2006-10-04 | — | — | EP | claimed |
| EP-1428820-B1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET SOC CIV (FR) | 2006-05-17 | — | — | EP | claimed |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | SCHWARTZ JEAN-CHARLES (FR) | 2004-11-04 | — | — | US | claimed |
| EP-1100503-B1 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | ILE BIOPROJET SOC CIV (FR) | 2004-09-22 | — | — | EP | claimed |
| EP-1428820-A1 | Non-imidazole alkylamines as histamine H-3-receptor ligands and their therapeutic applications | BIOPROJET (FR) | 2004-06-16 | — | — | EP | claimed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | claimed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | claimed |
| US-8486947-B2 | Treatment of Parkinson's disease, obstructive sleep apnea, dementia with Lewy bodies, vascular dementia with non-imidazole alkylamines histamine H3-receptor ligands | BIOPROJET (FR) | 2013-07-16 | — | — | US | disclosed |
| EP-1100503-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H 3?-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2001-05-23 | — | — | EP | disclosed |
| WO-2000006254-A2 | NON-IMIDAZOLE ALKYLAMINES AS HISTAMINE H3-RECEPTOR LIGANDS AND THEIR THERAPEUTIC APPLICATIONS | SOCIETE CIVILE BIOPROJET (FR) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318433-A1 | VERY FAST TIME RESOLVED IMAGING IN MULTIPARAMETER MEASUREMENT SPACE | HRH3, HRH4, HCRTR2 | HRH3 1/4885SLC6A2 147/4885HRH1 7/4885 |
| US-20040220225-A1 | central nervous system disorders; Alzheimer's disease; attention deficit disorders; cognition activators; psychological disorders; antidepressants | HTR1A, HRH4, HTR1D | HRH3 6/4885SLC6A2 96/4885HRH1 7/4885 |
| US-20090082353-A1 | TREATMENT OF EPILEPSY WITH NON-IMIDAZOLE ALKYLAMINES HISTAMINE H3-RECEPTOR LIGANDS | HRH3, HRH4, HRH2 | HRH3 1/4885SLC6A2 522/4885HRH1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.